Abstract
Excitation-inhibition (E:I) imbalance has long been considered one of the primary neurobiological theories explaining autism. However, the theory has been bolstered heavily by research on high-penetrance genetic mechanisms which are only found in a small proportion of the autism population and can manifest with potentially different directionality. How well does E:I imbalance explain idiopathic autistic males and does such E:I imbalance manifest in one particular direction? Answering this question in human patients necessitates a need for validated tools that allow for inference about E:I balance from non-invasively measured in-vivo electrophysiological (EEG, LFP) time-series data. Predictions from in-silico modelling alongside in-vivo validations from mouse electrophysiological data show that alterations of synaptic E:I balance cause changes in fractal long memory characteristics of the neural time-series that are captured with a metric known as the Hurst exponent (H). H estimated in resting state EEG data of idiopathic autistic males allows us to discover two distinct E:I ‘neurosubtypes’ that generalize at high levels (>92% accuracy) in independent data. Each autism neurosubtype captures approximately half of the sample and each can be described by opposing patterns of E:I imbalance relative to a typically-developing (TD) comparison group. Autism E:I neurosubtypes also show differential relationships between H and behavioral and demographic variables consisting of age, intelligence, and autism symptomatology. This work establishes causal evidence for interpreting changes in EEG-derived H as an E:I-relevant biomarker and suggests that idiopathic autistic males can be characterized by opposing types of E:I imbalance with differential phenotypic relevance.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This project was supported by funding from the Simons Foundation for Autism Research Initiative (SFARI; grant number 982347) to MVL and from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (grant agreement No 755816; AUTISMS) to MVL.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study used publicly available data from the CMI-HBN dataset. The CMI-HBN initiative received ethical approval by the Chesapeake Institutional Review Board, and written informed consent was obtained from all participants or their legal guardians (for participants < 18 years).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Intro, Methods, Results, and Discussion updated; Figure 1 and 2 added; added new authors; Supplemental files updated.
Data availability
CMI-HBN data can be found at http://fcon_1000.projects.nitrc.org/indi/cmi_healthy_brain_network/.
